These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15714973)

  • 21. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
    McDonald ML; Parsons JK
    Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the Specificity of PSA Screening with Serum and Urine Markers.
    Kearns JT; Lin DW
    Curr Urol Rep; 2018 Aug; 19(10):80. PubMed ID: 30105509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular diagnosis of prostate cancer.
    Canto EI; Shariat SF; Slawin KM
    Curr Urol Rep; 2004 Jun; 5(3):203-11. PubMed ID: 15161569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
    Sardana G; Dowell B; Diamandis EP
    Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biological markers of prostate cancer].
    Seitz C; Djavan B
    Ann Urol (Paris); 2006 Dec; 40(6):329-35. PubMed ID: 17214230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Status of PSA determination for early detection of prostate carcinoma].
    Hammerer P; Huland H
    Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
    Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tumor markers of urinary tract carcinoma].
    Kikuchi H
    Rinsho Byori; 2004 Apr; 52(4):371-80. PubMed ID: 15164607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate specific antigen: an updated review.
    So A; Goldenberg L; Gleave ME
    Can J Urol; 2003 Dec; 10(6):2040-50. PubMed ID: 14704108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.